BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 19455369)

  • 1. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization.
    Levy DE; Garber JE; Shields AE
    J Gen Intern Med; 2009 Jul; 24(7):822-8. PubMed ID: 19455369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.
    Hall MJ; Reid JE; Wenstrup RJ
    Cancer Prev Res (Phila); 2010 Dec; 3(12):1579-85. PubMed ID: 21149333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
    Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2.
    Adams I; Christopher J; Williams KP; Sheppard VB
    J Cancer Educ; 2015 Jun; 30(2):344-52. PubMed ID: 25301325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer surveillance behaviors in women presenting for clinical BRCA genetic susceptibility testing.
    Loescher LJ; Lim KH; Leitner O; Ray J; D'Souza J; Armstrong CM
    Oncol Nurs Forum; 2009 Mar; 36(2):E57-67. PubMed ID: 19273395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake of genetic counseling and multi-gene panel testing among women in the Intermountain West with previous negative BRCA1 and BRCA2 results contacted for updated testing.
    Mooney R; Espinel W; Elrick A; Kehoe K; Kohlmann W; Kaphingst KA
    J Genet Couns; 2022 Apr; 31(2):470-478. PubMed ID: 34570943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
    Bluman LG; Rimer BK; Regan Sterba K; Lancaster J; Clark S; Borstelmann N; Iglehart JD; Winer EP
    Psychooncology; 2003; 12(5):410-27. PubMed ID: 12833555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
    Bakos AD; Hutson SP; Loud JT; Peters JA; Giusti RM; Greene MH
    Health Expect; 2008 Sep; 11(3):220-31. PubMed ID: 18816319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
    PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
    Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
    Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Implementing B-RST
    Wernke K; Bellcross C; Gabram S; Ali N; Stanislaw C
    Clin Breast Cancer; 2019 Aug; 19(4):e547-e555. PubMed ID: 31005475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five Italian Families with Two Mutations in
    Vietri MT; Caliendo G; D'Elia G; Resse M; Casamassimi A; Minucci PB; Dello Ioio C; Cioffi M; Molinari AM
    Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33287145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community attitudes towards a Jewish community BRCA1/2 testing program.
    Cousens N; Kaur R; Meiser B; Andrews L
    Fam Cancer; 2017 Jan; 16(1):17-28. PubMed ID: 27480161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2005 Mar; 133A(2):165-9. PubMed ID: 15633195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.
    Høberg-Vetti H; Bjorvatn C; Fiane BE; Aas T; Woie K; Espelid H; Rusken T; Eikesdal HP; Listøl W; Haavind MT; Knappskog PM; Haukanes BI; Steen VM; Hoogerbrugge N
    Eur J Hum Genet; 2016 Jun; 24(6):881-8. PubMed ID: 26350514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.